From 4 to 16: What Fueled the 2025 Resurgence of Hong Kong Biotech IPOs?
In 2024, Hong Kong’s biotech IPO market hit rock bottom. Just four pre-revenue biotech companies listed under Chapter 18A — the lowest annual total since the regime was introduced in 2018[reference:0]. Twelve months later, the numbers told a completely different story: 16 biotech companies went public in 2025, a 300% surge in volume[reference:1]. How did Hong Kong’s biotech IPO market stage such a dramatic comeback in a single year?
This article breaks down the key drivers behind the 2025 resurgence — from global market回暖 and mainland China’s pro-innovation drug policies to HKEX’s pricing mechanism reforms. Whether you’re an investor, a financial institution, or a biotech company considering a Hong Kong listing, understanding this turnaround offers valuable insights into the cyclical nature of the market and the evolving policy landscape.
1. The Numbers: A Tale of Two Years
According to Wind data, 26 biotech companies (including 8 medical device and service firms) went public in Hong Kong in 2025, up from 9 in 2024. Total actual fundraising reached HK$292.65 billion, representing a staggering 751.7% year-on-year increase[reference:2][reference:3].
Among these, 16 unprofitable biotech companies listed under Chapter 18A, raising a combined HK$137.71 billion — accounting for 47.06% of the entire biotech sector’s IPO proceeds[reference:4]. By comparison, only 4 unprofitable companies listed under the same rule in 2024[reference:5].
2. What Drove the Resurgence?
The 2025 rebound wasn’t a coincidence. It was the result of three converging forces: global market recovery, supportive policy measures from mainland China, and targeted regulatory reforms by HKEX.
2.1 Global Market recovery and Investor Sentiment
After a prolonged downturn in 2023–2024, global equity markets showed signs of recovery in 2025. Risk appetite returned, and investors began reallocating capital toward high-growth sectors — including biotechnology. Hong Kong, as a gateway to Chinese innovation assets, benefited directly from this shift.
The broader Hong Kong IPO market also delivered exceptional performance. Deloitte estimated that 114 IPOs would be completed in Hong Kong in 2025, raising approximately HK$286.3 billion — a 63% increase in deal volume and more than triple the proceeds from the previous year[reference:6]. This enabled Hong Kong to overtake Nasdaq as the world’s largest IPO hub by funds raised in 2025[reference:7].
Within this context, biotech stood out as a star performer. The Hang Seng Innovative Drug Index surged approximately 110% year-to-date as of September 2025[reference:8], reflecting strong market confidence in the sector.
2.2 Mainland China’s Pro-Innovation Drug Policies
2025 marked a turning point for China’s innovation drug policy environment. The Government Work Report for the first time explicitly called for “formulating an innovative drug catalogue and supporting the development of innovative drugs”[reference:9] — a clear signal that the central government was prioritizing biopharmaceutical innovation.
Regulatory bodies also stepped up. The National Medical Products Administration and the National Healthcare Security Administration coordinated efforts to accelerate new drug review and approval processes and implement commercial insurance coverage for innovative drugs[reference:10]. These measures created a more predictable and supportive environment for biotech companies — both for their R&D pipelines and their ability to attract capital.
In addition, the “1+” mechanism introduced by the Hong Kong SAR government in November 2023 allowed new drugs with qualified local clinical data to apply for registration more efficiently[reference:11]. This further lowered the barrier for innovative drug companies to operate in and access the Hong Kong market.
2.3 HKEX Regulatory Reforms: The TECH Channel and Pricing Mechanism Changes
Perhaps the most direct catalyst for the 2025 surge was HKEX’s own regulatory innovation.
In May 2025, HKEX and the Securities and Futures Commission launched the TECH Channel, a dedicated platform for biotech and specialist technology companies[reference:12][reference:13]. The channel allows eligible companies to submit listing applications on a confidential basis — a significant departure from the traditional public filing process. This reduces preparation timelines, lowers compliance costs, and protects sensitive commercial information[reference:14].
By the end of 2025, 119 applications had been received through the TECH Channel, including 73 from pre-revenue biotech companies. The channel has been widely welcomed by the market and is credited with significantly accelerating the listing pipeline.
HKEX also introduced pricing mechanism reforms in 2025. The first company to list under the new rules was 银诺医药 (Vigonvita), which made its debut on August 15, 2025[reference:15]. The new mechanism provided greater flexibility in pricing and allocation, making IPOs more attractive to both issuers and investors.
3. Star Performers: The IPO Highlights of 2025
The 2025 18A class delivered some of the most spectacular first-day performances in Hong Kong IPO history. The average first-day gain for 18A companies reached 69.4% — more than double the market average[reference:16].
Top First-Day Gainers
| Company | Listing Date | First-Day Gain |
|---|---|---|
| 银诺医药-B (Vigonvita) | August 15, 2025 | +206.48% |
| 中慧生物-B (Zhonghui Biotech) | August 11, 2025 | +157.98% |
| 旺山旺水-B (Wangsheng Wangshui) | November 6, 2025 | +145.73% |
| 宝济药业-B (Baoji Pharma) | December 10, 2025 | +138.82% |
| 轩竹生物-B (Xuanzhu Biotech) | October 15, 2025 | +126.72% |
| 映恩生物-B (Dingxin Biotech) | April 15, 2025 | +116.70% |
映恩生物 (Dingxin Biotech): Despite a broader market pullback during its IPO period, the company’s public offering tranche was 115.14 times oversubscribed, while the international tranche was oversubscribed 13.52 times — setting a new 18A IPO subscription record[reference:17]. The company attracted 15 cornerstone investors and became the largest 18A offering since 2022[reference:18].
银诺医药 (Vigonvita): As the first company to list under HKEX’s new pricing mechanism, Vigonvita debuted with a 206% gain, delivering a profit of HK$7,714 per board lot[reference:19]. The stock’s performance validated the new pricing rules and set a positive tone for subsequent 18A listings.
Another notable mention: 维立志博-B (Vital Biotech), which listed in July 2025, achieved a retail subscription ratio of 3,494 times, attracting over HK$330 billion in subscription funds[reference:20].
Across the full year, 7 out of the 18 stocks that doubled on their first day of trading came from the 18A biotech sector[reference:21].
4. Not All Sunshine: The Year-End Cooling
While the first three quarters of 2025 were exceptionally strong, the year ended on a mixed note. In December, two consecutive 18A IPOs — 华芢生物-B (Huaren Biotech) and 翰思艾泰-B (Hansight AI) — broke through on their first trading day, with Hansight AI falling by as much as 46.25%[reference:22][reference:23].
This sudden shift in sentiment highlighted the volatility and differentiation within the 18A market. While companies with late-stage pipelines and clear commercialisation pathways continued to attract strong demand, earlier-stage companies with less differentiated assets faced increasing scrutiny from investors[reference:24].
Of the 16 18A companies listed in 2025, 4 experienced first-day losses, underscoring that the resurgence was not uniform across the board[reference:25].
5. What This Means for Investors and Companies
For overseas investors, the 2025 data confirms that Hong Kong’s 18A market is not just a funding channel — it has evolved into a global pricing and value discovery platform for Chinese biotech innovation. The strong first-day performances and robust subscription demand reflect growing international confidence in the quality of Chinese biotech assets.
However, the year-end cooling also serves as a warning: the window of opportunity is not open to everyone. Companies with differentiated technology, strong IP protection, and clear commercial pathways will continue to command premium valuations. Those that lack these attributes may struggle to attract sufficient demand, even in a buoyant market.
For biotech companies considering a Hong Kong IPO, the 2025 experience offers several lessons:
- Timing matters: The first three quarters of 2025 provided a much more favorable window than the year-end period.
- Pipeline quality is paramount: Investors are scrutinising clinical data quality, global rights structures, and commercialisation timelines more than ever.
- Regulatory readiness: The TECH Channel has made the process faster and more confidential — but companies still need to be thoroughly prepared.
For financial institutions and professional services firms advising on cross-border transactions, the 2025 data reinforces the importance of rigorous due diligence. Understanding a company’s registration status, credit history, legal risk profile, and corporate governance standards is essential for making informed decisions.
Whether you are evaluating a potential investment, conducting due diligence on a Chinese biotech partner, or seeking to verify the credentials of a company that has listed — or is planning to list — on the HKEX, access to verified, official company information is non-negotiable. Services that provide official enterprise credit reports and professional due diligence reports can help bridge the information gap, enabling more confident decision-making.
6. Looking Ahead: What to Expect in 2026 and Beyond
The pipeline for 2026 remains robust. As of June 30, 2026, there were 38 active Chapter 18A listing applications pending. With HKEX continuing to refine its regulatory framework and mainland China maintaining its pro-innovation policy stance, the conditions that fueled the 2025 resurgence are likely to persist.
However, the market is also maturing. Investors are becoming more sophisticated, and the “easy money” phase may be over. Companies that can demonstrate real-world clinical progress, credible commercialisation plans, and strong corporate governance will continue to find a receptive market. Those that cannot may face an increasingly challenging environment.
For overseas stakeholders, the message is clear: Hong Kong’s biotech market is open for business, but success requires diligence, expertise, and reliable information.
ChinaBizInsight
Your strategic bridge to transparent business in China.